IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Nature Biotechnology

• Publication date

  2018-03-05

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1038/nbt.4086PMID 29505028
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• CCL21/CCR7 Axis Contributed to CD133+ Pancreatic Cancer Stem-Like Cell Metastasis via EMT and Erk/NF-κB Pathway

  2016cited by this paper
• Murine mesothelin: characterization, expression, and inhibition of tumor growth in a murine model of pancreatic cancer

  2016cited by this paper
• Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells.

  2015cited by this paper
• Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy.

  2015cited by this paper
• Adoptive cell transfer as personalized immunotherapy for human cancer

  2015cited by this paper
• CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia.

  2015cited by this paper
• CCL21-CCR7 promotes the lymph node metastasis of esophageal squamous cell carcinoma by up-regulating MUC1

  2015cited by this paper
• Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy

  2015cited by this paper
• Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic.

  2015cited by this paper
• Fibroblastic Reticular Cells: Organization and Regulation of the T Lymphocyte Life Cycle

  2015cited by this paper
• Improving the safety of cell therapy with the TK-suicide gene

  2015cited by this paper
• Engineering CAR-T cells: Design concepts.

  2015cited by this paper
• Novel activating mutations lacking cysteine in type I cytokine receptors in acute lymphoblastic leukemia.

  2014cited by this paper
• CAR T Cells for Solid Tumors: Armed and Ready to Go?

  2014cited by this paper
• Type 1 interferon-induced IL-7 maintains CD8+ T-cell responses and homeostasis by suppressing PD-1 expression in viral hepatitis

  2014cited by this paper
• CD19-CAR Trials

  2014cited by this paper
• CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results.

  2012cited by this paper
• Protein L: a novel reagent for the detection of Chimeric Antigen Receptor (CAR) expression by flow cytometry

  2012cited by this paper
• Redirecting Gene-Modified T Cells toward Various Cancer Types Using Tagged Antibodies

  2012cited by this paper
• IL-7 receptor blockade reverses autoimmune diabetes by promoting inhibition of effector/memory T cells

  2012cited by this paper
• IL-7 Abrogates Suppressive Activity of Human CD4+CD25+FOXP3+ Regulatory T Cells and Allows Expansion of Alloreactive and Autoreactive T Cells

  2012cited by this paper
• Cloning, expression, and purification of monoclonal antibodies in scFv-Fc format.

  2012cited by this paper
• Use of the 2A Peptide for Generation of Multi-Transgenic Pigs through a Single Round of Nuclear Transfer

  2011cited by this paper
• Gain-of-function mutations in interleukin-7 receptor-α (IL7R) in childhood acute lymphoblastic leukemias

  2011cited by this paper
• IL-7 engages multiple mechanisms to overcome chronic viral infection and limit organ pathology.

  2011cited by this paper
• Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia

  2011cited by this paper
• High Cleavage Efficiency of a 2A Peptide Derived from Porcine Teschovirus-1 in Human Cell Lines, Zebrafish and Mice

  2011cited by this paper
• Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.

  2010cited by this paper
• Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication.

  2010cited by this paper
• Cancer esearch oenvironment and Immunology plifying TLR-MyD 88 Signals within Tumor-Specific ells Enhances Antitumor Activity to Suboptimal R els of Weakly Immunogenic Tumor

  2010cited by this paper
• Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.

  2009cited by this paper
• Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies

  2009cited by this paper
• Cyclophosphamide Enhances the Antitumor Efficacy of Adoptively Transferred Immune Cells through the Induction of Cytokine Expression, B-Cell and T-Cell Homeostatic Proliferation, and Specific Tumor Infiltration

  2007cited by this paper
• Fibroblastic reticular cells in lymph nodes regulate the homeostasis of naive T cells

  2007cited by this paper
• Cell biology of IL-7, a key lymphotrophin.

  2005cited by this paper
• IL-7: maintaining T-cell memory and achieving homeostasis.

  2005cited by this paper
• Differing Activities of Homeostatic Chemokines CCL19, CCL21, and CXCL12 in Lymphocyte and Dendritic Cell Recruitment and Lymphoid Neogenesis1

  2002cited by this paper
• Interleukin-7: master regulator of peripheral T-cell homeostasis?

  2001cited by this paper
• Suicide genes: past, present and future perspectives.

  2000cited by this paper
• Coexpression of the chemokines ELC and SLC by T zone stromal cells and deletion of the ELC gene in the plt/plt mouse.

  2000cited by this paper
• CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs.

  1999cited by this paper
• The CC Chemokine Receptor-7 Ligands 6Ckine and Macrophage Inflammatory Protein-3β Are Potent Chemoattractants for In Vitro- and In Vivo-Derived Dendritic Cells

  1999cited by this paper
• The CC chemokine receptor-7 ligands 6Ckine and macrophage inflammatory protein-3 beta are potent chemoattractants for in vitro- and in vivo-derived dendritic cells.

  1999cited by this paper
• Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.

  1998cited by this paper
• EBI1-ligand chemokine (ELC) attracts a broad spectrum of lymphocytes: activated T cells strongly up-regulate CCR7 and efficiently migrate toward ELC.

  1998cited by this paper

• CAR-T cells co-expressing IL-7 and CCL19 promote epitope spreading to enhance antitumor immunity

  2026influential citation
• Nano-/nanobio-technology-enhanced CAR-T cell therapy: engineering the next generation of immunotherapies

  2026cites this paper
• Engineering the next generation of CAR T- cells: precision modifications, logic gates and universal strategies to overcome exhaustion and tumor resistance

  2026cites this paper
• Engineered Bacterial Biomaterials for Augmenting Adoptive Immune Cell Therapy Against Solid Tumors.

  2026cites this paper
• T cell immunotherapy for solid tumors: limitations, progress, and future prospects

  2026cites this paper
• CAR-T Cell Exhaustion in cancer Over the Past Decade: Mitochondrial Metabolism as a Target for Counteraction.

  2026cites this paper
• IL-5 CAR-T cell therapy induces effective remission in hypereosinophilic disorders.

  2026cites this paper
• From mechanisms to therapy: the role of tertiary lymphoid structures in bladder cancer

  2026cites this paper
• CAR-T cell therapies are coming after glioblastoma: An overview of early phase clinical trials and future perspectives

  2026cites this paper
• TIPE2 knockdown enhances the anti-tumor efficacy of NKG2D CAR-T cells against pancreatic cancer via activating NF-κb signaling pathway.

  2026cites this paper
• Enhancement of B7-H3 chimeric antigen receptor-T cell efficacy via the coexistence effect of IL-7, IL-15 and CCL19 for pancreatic and lung xenograft tumors.

  2026cites this paper
• Engineering Immunity: Current Progress and Future Directions of CAR-T Cell Therapy

  2026cites this paper
• Strategies and mechanisms for the enhancement of chimeric antigen receptor T-cell functions.

  2026cites this paper
• Gasdermin E-mediated lysosome-pore formation curbs pancreatic ductal adenocarcinoma via IFN-γ/IFN-β/TGF-β cocktail mRNA-LNP

  2026cites this paper
• Next generation CAR-T cells to tackle down solid tumors.

  2026cites this paper
• Methods and applications of patient-derived organoid models for immune microenvironment and immunotherapy research in multiple cancer types

  2026cites this paper
• Evaluation of Clinical and Prognostic Roles of CCL8 in Urinary Bladder Cancer and Upper Tract Urothelial Carcinoma.

  2026cites this paper
• CXCR4 induces memory formation over exhaustion in CAR-T cells to achieve durable leukemia targeting

  2026cites this paper
• Functional genomics for improving adoptive T-cell transfer therapies

  2025cites this paper
• CCL19-armed recombinant influenza virus inhibited colorectal cancer growth by remodeling tumor microenvironment

  2025cites this paper
• Multifunctional extracellular vesicles inhibiting autophagy ameliorate immunotherapy in non-small cell lung cancer

  2025cites this paper
• Fine tuning towards the next generation of engineered T cells

  2025cites this paper
• Overcoming solid-tumor barriers: armored CAR-T cell therapy.

  2025cites this paper
• GD2TIF cells as a platform for single-dose and long-term delivery of biologics

  2025influential citation
• Designing immunity with cytokines: A logic-based framework for programmable CAR therapies.

  2025cites this paper
• Advancing CAR-T Therapy for Solid Tumors: From Barriers to Clinical Progress

  2025cites this paper
• Study on the in vitro and in vivo killing effects of PD-1 antibody-secreting c-Met-targeted CAR-T cells on esophageal cancer cell line ECA109

  2025cites this paper
• Integration of a novel anti-PD-1 antibody with chimeric antigen receptor-T engineered to express interleukin-7 enhances targeting efficacy against lung cancer

  2025cites this paper
• From concept to cure: Molecular mechanisms, clinical triumphs, and future horizons of chimeric antigen receptor T-cell therapy

  2025cites this paper
• Improved Antitumor Activity of Interleukin-12-Secreting Chimeric Antigen Receptor T Cells Targeting CD176 across Different Carcinomas.

  2025cites this paper
• Current strategies for armoring chimeric antigen receptor T-cells to overcome barriers of the solid tumor microenvironment

  2025cites this paper
• Turning cold tumors into hot tumors to ignite immunotherapy

  2025cites this paper
• Next-generation CAR-T cells design: leveraging tumor features for enhanced efficacy

  2025cites this paper
• hCCL19-expressing recombinant Newcastle disease virus boosts CAR T cell infiltration and efficacy in solid tumor

  2025cites this paper
• Tumour-associated vasculature in T cell homing and immunity: opportunities for cancer therapy

  2025cites this paper
• Adoptive cell therapy for cancer: combination strategies and biomarkers

  2025cites this paper
• Preclinical and clinical evaluation of intratumoral injection of an IL-12 expressing SKV-012 oncolytic virus for advanced solid tumors

  2025cites this paper
• Personalized CRISPR knock-in cytokine gene therapy to remodel the tumor microenvironment and enhance CAR T cell therapy in solid tumors

  2025cites this paper
• Combinational therapeutic strategies to overcome resistance to immune checkpoint inhibitors

  2025cites this paper
• Novel CAR-T Cells Specifically Targeting Nectin4 Exhibit Effective Anti-Tumor Efficacy in Bladder Cancer Cell Lines

  2025cites this paper
• Enhancing mesothelin CAR T cell therapy for pancreatic cancer with an oncolytic herpes virus boosting CAR target antigen expression

  2025cites this paper
• Camrelizumab Combined with Lenvatinib and RALOX-Hepatic Arterial Infusion Chemotherapy for Unresectable Hepatocellular Carcinoma (Cal Era): A Prospective, Single-Arm, Phase II Trial

  2025cites this paper
• Innovative approaches to CAR-T cell therapy: the role of lipid metabolism pathways

  2025cites this paper
• Barriers and solutions for CAR-T therapy in solid tumors

  2025cites this paper
• Rewiring endogenous genes in CAR T cells for tumour-restricted payload delivery

  2025cites this paper
• Reshaping tumor immune microenvironment and modulating T cell function based on hierarchical nanotherapeutics for synergistically inhibiting osteosarcoma

  2025cites this paper
• Challenges in the preclinical design and assessment of CAR-T cells

  2025cites this paper
• Recent advances in universal chimeric antigen receptor T cell therapy

  2025cites this paper
• Strategies and challenges in promoting chimeric antigen receptor T cells trafficking and infiltration of solid tumors

  2025cites this paper
• Dendritic cells: understanding ontogeny, subsets, functions, and their clinical applications

  2025cites this paper
• Engineering a Multilayered 3D Stromal Barrier Model for Quantitative Analysis of T Cell Infiltration and Cytotoxicity.

  2025cites this paper
• CAR-T cells in solid tumors: Challenges and breakthroughs

  2025cites this paper
• Optogenetic Engineered Macrophages for Light-Induced M1 Polarization and Enhanced Chemo-Immunotherapy in Melanoma Models.

  2025cites this paper
• Engineering adoptive cell therapy for solid tumors

  2025cites this paper
• Multiplex engineering and multifunction T cells for precise and effective immunotherapies

  2025cites this paper
• Causal effects and mediation pathways of circulating plasma proteins on osteoporosis: a two-sample and two-step Mendelian randomization study

  2025influential citation
• The crosstalk between probiotics and T cell immunity

  2025cites this paper
• Precision Reprogramming in CAR-T Cell Therapy: Innovations, Challenges, and Future Directions of Advanced Gene Editing

  2025cites this paper
• Harnessing the potential of gene editing technology for CAR-T cell therapy of solid tumors

  2025cites this paper
• Hub genes and common pathogenic mechanisms between COPD and H. pylori infection

  2025cites this paper
• Mechanistic insights into the limited function of CAR-T cells in solid tumors and potential solutions.

  2025cites this paper
• CAR-T cell exhaustion in B cell lymphoma: Current status, mechanisms, and potential solutions

  2025cites this paper
• Tracing the development of CAR-T cell design: from concept to next-generation platforms

  2025cites this paper
• The clinical landscape of CAR NK cells

  2025cites this paper
• CD24-targeted CAR-T cells mediated long-term anti-tumor efficacy through activation of endogenous tumor immune responses.

  2025cites this paper
• Inflammation-triggering Engineered Macrophages (MacTriggers) Are Promising Cell-based Therapeutic Avenues for Chemoresistant Solid Tumors

  2025cites this paper
• Cellular Kinetics and Biodistribution of Adoptive T Cell Therapies: from Biological Principles to Effects on Patient Outcomes

  2025cites this paper
• Strategies to Overcome Antigen Heterogeneity in CAR-T Cell Therapy

  2025cites this paper
• IL-7 Immunotherapies: Current Applications and Engineering Opportunities

  2025influential citation
• Presetting CAR-T cells during ex vivo bio-manufacturing.

  2025cites this paper
• Precise CAR-T-cell Therapy Targeting Non-Cancerous Diseases: Advances in Precision Medicine and Bioengineering

  2025cites this paper
• CD22 TCR-engineered T cells exert antileukemia cytotoxicity without causing inflammatory responses

  2025cites this paper
• Tumor Microenvironment-Responsive Nano-Immunomodulators for Enhancing Chimeric Antigen Receptor-T Cell Therapy in Lung Cancer.

  2025cites this paper
• Neoleukin-2/15-armored CAR-NK cells sustain superior therapeutic efficacy in solid tumors via c-Myc/NRF1 activation

  2025cites this paper
• Chemokines and their receptors in the esophageal carcinoma tumor microenvironment: key factors for metastasis and progression

  2025cites this paper
• Novel immune drug combination induces tumour microenvironment remodelling and reduces the dosage of anti-PD-1 antibody

  2025cites this paper
• Enhanced anti−tumor efficacy of “IL−15 and CCL19” −secreting CAR−T cells in human glioblastoma orthotopic xenograft model

  2025cites this paper
• Leveraging Vitamin C to Augment Nanoenabled Photothermal Immunotherapy.

  2025cites this paper
• CAR-T therapy in solid tumors.

  2025cites this paper
• SOHO State of the Art Updates and Next Questions | CD7 CAR-T Therapy for Treating CD7-Positive Hematological Malignancies: Clinical Advances and Future Directions.

  2025cites this paper
• Dendritic cells instruct T cell anti-tumor immunity and immunotherapy response

  2025cites this paper
• Strategies to overcome tumour relapse caused by antigen escape after CAR T therapy

  2025cites this paper
• Advances and challenges in CAR-T cell therapy for head and neck squamous cell carcinoma

  2025cites this paper
• Trifunctional antibody-cytokine fusion protein formats for tumor-targeted combination of IL-15 with IL-7 or IL-21

  2025cites this paper
• Effectiveness, Limitations, and Future Perspectives of CAR-T Cell Therapy in Solid Tumor Treatment: A Narrative Review

  2025cites this paper
• In vivo CAR engineering for immunotherapy

  2025cites this paper
• Preferential tumor targeting of HER2 by iPSC-derived CAR T cells engineered to overcome multiple barriers to solid tumor efficacy.

  2025cites this paper
• Co-expression of IL-15 and CCL21 strengthens CAR-NK cells to eliminate tumors in concert with T cells and equips them with PI3K/AKT/mTOR signal signature

  2025cites this paper
• CD137 might be a pivotal regulator of Th1/Th17-driven autoimmunity and B-cell hyperactivity in hyperthyroidism.

  2025cites this paper
• The challenges and progress of CAR-T cell therapy in the treatment of solid tumors

  2025cites this paper
• Immune profiling identifies CD161+CD127+CD8+ T cells as a predictive biomarker for Anti-PD-L1 therapy response in the SCLC-I subtype

  2025cites this paper
• CAR-Based Cell Therapy in Head and Neck Cancer: A Comprehensive Review on Clinical Applicability

  2025cites this paper
• Human iPSC-derived NK cells armed with CCL19, CCR2B, high-affinity CD16, IL-15, and NKG2D complex enhance anti-solid tumor activity

  2025cites this paper
• The Impact of Various Cellular Product Characteristics on the Efficacy of Anti-CD19 Therapy with T-Lymphocytes Modified with Chimeric Antigen Receptor

  2025cites this paper
• Lifespan‐Regulated CAR‐Macrophages from Myeloid Progenitors for Enhanced Colorectal Cancer Therapy

  2025cites this paper
• CAR-T cell therapy in china: innovations, challenges, and strategic pathways

  2025cites this paper
• Directed evolution-based discovery of ligands for in vivo restimulation of chimeric antigen receptor T cells.

  2025cites this paper
• Engineered T cells stimulate dendritic cell recruitment and antigen spreading for potent anti-tumor immunity

  2025cites this paper
• Synthetic Biology and Biomaterials Strategies to Deceive the Tumor Microenvironment in CAR‐T Immunotherapy

  2025cites this paper
• Unlocking the potential of engineered immune cell therapy for solid tumors

  2025cites this paper